Cleveland Clinic performs world’s first in-human gene therapy for hypertrophic cardiomyopathy.
Cleveland Clinic has infused a new gene therapy to deliver a working gene to address the leading cause of hypertrophic cardiomyopathy (HCM) in the first patient in the world as part of a clinical trial. Myosin binding protein C3 (MYBPC3)…